MedTrace Logo

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

NCT00542022 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2015-10-20

No results posted yet for this study

Summary

To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

MK0812 / Duration of Treatment: 12 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2005-05-31
Completion
2005-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542022 on ClinicalTrials.gov